Experimental gene therapy offers hope for rare blindness condition
NCT ID NCT07307469
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study provides ZVS101e, a gene therapy, to 32 people with Bietti crystalline corneoretinal dystrophy (BCD) who were in the control group of a previous Phase III trial. The therapy uses a harmless virus to deliver a working gene to the eye, aiming to slow vision loss. The main goal is to check safety and side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ZVS101e (a gene therapy using a harmless virus to deliver a working copy of the CYP4V2 gene into eye cells)
- What this could lead to
- If it works, this could offer a treatment option for people with Bietti crystalline dystrophy, potentially slowing vision loss.
- What could go wrong
- This is an early compassionate-use study with only 32 participants, so results may not apply widely. Gene therapies can cause inflammation or other side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BIETTI CRYSTALLINE CORNEORETINAL DYSTROPHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Henan Provincial People's Hospital
Zhengzhou, Henan, China
-
Peking University Third Hospital
Beijing, Beijing Municipality, China
-
Tianjin Medical University Eye Hospital
Tianjin, Tianjin Municipality, China
-
West China Hospital, Sichuan University
Chengdu, Sichuan, China
-
Zhongshan Ophthalmic Center, Sun Yat-sen University
Guangzhou, Guangdong, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.